Status:

UNKNOWN

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Lead Sponsor:

Samsung Medical Center

Conditions:

Cardiotoxicity

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy i...

Detailed Description

Despite the left ventricular global longitudinal strain (GLS) enables early prediction of trastuzumab-related cardiomyopathy, its clinical application has been hampered due to the lack of appropriate ...

Eligibility Criteria

Inclusion

  • Female aged ≥ 18 years
  • Pathologically confirmed HER2-positive breast cancer
  • Adjuvant treatment plan comprises at least 12 cycles of Trastuzumab
  • Baseline echocardiogram should be performed before starting trastuzumab
  • Cumulative anthracycline dose ≤ 300mg/m2
  • Written informed consent to participate in the study

Exclusion

  • History of hypersensitivity or alllergic reaction to the study medication
  • Metastatic breast cancer
  • Treatment with angiotensin converting enzyme(ACE) inhibitor , Angiotensin receptor blocker (ARB), beta-blocking agents, or diuretics
  • Patients with NCI/CTCAE grade ≥ 2 congestive heart failure, myocardial infarction, symptomatic left ventricular systolic dysfunction, heart's valve disease (≥ moderate), arrhythmias (Grade ≥ 3) \< 12 months before enrollment
  • Pregnancy or breast feeding
  • Baseline systolic pressure \< 90mmHg
  • Cumulative anthracycline dose \> 300mg/m2
  • Serious concurrent illness

Key Trial Info

Start Date :

July 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 18 2023

Estimated Enrollment :

136 Patients enrolled

Trial Details

Trial ID

NCT04429633

Start Date

July 19 2019

End Date

July 18 2023

Last Update

June 12 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Samsung Medical Center

Seoul, South Korea, 06351